ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect.
Curr Drug Targets
; 22(16): 1832-1843, 2021.
Article
in English
| MEDLINE | ID: covidwho-1511929
ABSTRACT
ACE2 has long been known as an injury protective protein, which can protect against a variety of organ damage such as the heart, liver, kidney, and lung. Especially in cardiovascular diseases, as a negative regulator of RAAS, ACE2 is an extremely important protective factor that mainly plays a role by converting Ang II to Ang-(1-7). Nevertheless, with the recent outbreak of COVID-19, it is exposed that another identity of ACE2 is the entry receptor for SARS-CoV-2, which previously serves as the entry receptor for SARS. With the in-depth clinical research, it is found that the severity and susceptibility of COVID-19 are related to cardiovascular diseases, and SARS-CoV-2 binding to ACE2 receptor is also potentially associated with heart injury symptoms. Therefore, in this article, we mainly summarize the relationship between ACE2, COVID-19, and cardiovascular diseases/heart injury.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Angiotensin-Converting Enzyme 2
/
COVID-19
/
Heart Injuries
Type of study:
Etiology study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Curr Drug Targets
Journal subject:
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
1389450122666210319110320
Similar
MEDLINE
...
LILACS
LIS